It was a rough year for biotech stocks — the Nasdaq Biotech Index fell 22 percent even as the Dow gained 13 percent and the Nasdaq gained 8 percent.
The university claims that Genia's patents are based on technology that was developed by UCSC researchers and that UCSC should have ownership of them.
The test runs on the firm's high throughput platforms and has claims for extragenital samples in addition to traditional samples.
Mergers and acquisitions in the omics space rose for the second year in a row, but the increase was significantly less than the 33 percent uptick in 2015 deals.
Roche said the timeline to launch a diagnostic system and assays based on PacBio's technology would be too long; instead, it will focus on commercializing Genia's technology.
In October, Roche reported the tissue diagnostics business contributed 8 percent to diagnostics sales in the first nine months of 2016.
The two companies struck a $75 million deal in 2013 to launch a sequencing system and assays for the diagnostic market.
Under the agreement, Roche Diagnostics will offer Good Start's GeneVu carrier screening test along with its Harmony NIPT.
The agreement now includes distribution of Roche's Kapa Biosystems portfolio in all geographies except the US, Brazil, and Japan.
In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.
Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.
Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.
In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.